Allink Biotherapeutics is at the forefront of developing innovative biotherapeutics, particularly focusing on bispecific antibodies and antibody-drug conjugates (ADCs). The company utilizes a proprietary bispecific antibody platform, known as STAR-Lite, which allows for the creation of bispecific ADCs with optimized drug-to-antibody ratios (DARs), enhanced hydrophilicity, and superior stability. This platform is designed to avoid light chain mismatches and is capable of one-cell manufacturing, which streamlines the development process. Additionally, Allink employs the Hy-BEAM platform for ADC development, which features site-specific conjugation and hydrophilic linkers that enhance therapeutic efficacy and safety profiles. This combination of technologies positions Allink to address unmet medical needs in oncology and immunology.

The company’s robust pipeline includes multiple lead candidates targeting various solid tumors and immunological conditions, with several projects expected to enter the investigational new drug (IND) stage in the near future. Allink's bispecific ADCs are designed to improve target specificity and expand therapeutic windows by simultaneously inhibiting multiple signaling pathways and enhancing internalization rates of the drug. This innovative approach not only aims to overcome drug resistance commonly seen in traditional therapies but also seeks to minimize off-target effects, thereby increasing the safety and efficacy of treatments. With a strong intellectual property portfolio and a commitment to advancing its technologies, Allink Biotherapeutics is poised to make significant contributions to the biopharmaceutical landscape.

China

Founded in 2023 and based in Shanghai, China, Allink Biotherapeutics is a biotech company dedicated to expediting the development of a diverse pipeline of FIC/BIC therapeutic candidates for oncology and immune diseases.

Our goal is to harness our proprietary bispecific antibody and ADC technology platforms, along with efficient execution and business collaboration , to address critical unmet clinical needs.

Allink Biotherapeutics

Company Details